secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0001213900-23-070110
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus CEO and Chairman steps down; interim Co-Presidents appointed
-------------------------------------------------------------------

- Yutaka Niihara, M.D., Ph.D., leaves CEO and Chairman roles effective Aug 18, 2023, to pursue other projects; remains a director.
- Willis Lee (COO) and George Sekulich (CIO) appointed interim Co-Presidents pending CEO search.
- George Sekulich's base salary set at $210,000; eligible for stock plan awards.
- Company to focus on Endari sales in U.S. and MENA, expects generic competition in 2024.
- Discontinuing non-Endari activities to reduce operating costs and improve cash flow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390023070110/0001213900-23-070110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390023070110/ea184081-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-070110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer